Strategies and challenges for the next generation of antibody–drug conjugates
作者： Alain Beck , Liliane Goetsch , Charles Dumontet , Nathalie Corvaïa
DOI: 10.1038/NRD.2016.268
关键词:
摘要: Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that are evaluating more than 60 further ADC candidates. The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked …
nature.com
sci-hub.se 参考文章(174)
Gregory S. Hamilton, Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids. Biologicals. ,vol. 43, pp. 318- 332 ,(2015) , 10.1016/J.BIOLOGICALS.2015.05.006
Robert V. Kolakowski, Thomas D. Young, Philip W. Howard, Scott C. Jeffrey, Peter D. Senter, Synthesis of a C2-aryl-pyrrolo[2,1-c][1,4]benzodiazepine monomer enabling the convergent construction of symmetrical and non-symmetrical dimeric analogs Tetrahedron Letters. ,vol. 56, pp. 4512- 4515 ,(2015) , 10.1016/J.TETLET.2015.05.116
Michael P. VanBrunt, Kurt Shanebeck, Zachary Caldwell, Jeffrey Johnson, Pamela Thompson, Thomas Martin, Huifang Dong, Gary Li, Hengyu Xu, Francois D’Hooge, Luke Masterson, Pauline Bariola, Arnaud Tiberghien, Ebele Ezeadi, David G. Williams, John A. Hartley, Philip W. Howard, Kenneth H. Grabstein, Michael A. Bowen, Marcello Marelli, Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry. Bioconjugate Chemistry. ,vol. 26, pp. 2249- 2260 ,(2015) , 10.1021/ACS.BIOCONJCHEM.5B00359
David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan, Edmund A. Rossi, Robert M. Sharkey, Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) Oncotarget. ,vol. 6, pp. 22496- 22512 ,(2015) , 10.18632/ONCOTARGET.4318
Pavel Strop, Kathy Delaria, Davide Foletti, Jody Melton Witt, Adela Hasa-Moreno, Kris Poulsen, Meritxell Galindo Casas, Magdalena Dorywalska, Santiago Farias, Ariel Pios, Victor Lui, Russell Dushin, Dahui Zhou, Thayalan Navaratnam, Thomas-Toan Tran, Janette Sutton, Kevin C Lindquist, Bora Han, Shu-Hui Liu, David L Shelton, Jaume Pons, Arvind Rajpal, Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading Nature Biotechnology. ,vol. 33, pp. 694- 696 ,(2015) , 10.1038/NBT.3274
Robert P Lyon, Tim D Bovee, Svetlana O Doronina, Patrick J Burke, Joshua H Hunter, Haley D Neff-LaFord, Mechthild Jonas, Martha E Anderson, Jocelyn R Setter, Peter D Senter, Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nature Biotechnology. ,vol. 33, pp. 733- 735 ,(2015) , 10.1038/NBT.3212
SY Kim, JW Theunissen, J Balibalos, S Liao-Chan, MC Babcock, T Wong, B Cairns, D Gonzalez, EH Van Der Horst, M Perez, Z Levashova, L Chinn, JA D‘Alessio, M Flory, A Bermudez, DY Jackson, E Ha, J Monteon, MF Bruhns, G Chen, TS Migone, None, A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies Blood Cancer Journal. ,vol. 5, ,(2015) , 10.1038/BCJ.2015.39
Roger R. Beerli, Tamara Hell, Anna S. Merkel, Ulf Grawunder, Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency PLOS ONE. ,vol. 10, ,(2015) , 10.1371/JOURNAL.PONE.0131177
, Why is it so difficult to use gemtuzumab ozogamicin Blood. ,vol. 121, pp. 4813- 4814 ,(2013) , 10.1182/BLOOD-2013-05-498683
R. James Christie, Ryan Fleming, Binyam Bezabeh, Rob Woods, Shenlan Mao, Jay Harper, Augustine Joseph, Qianli Wang, Ze-Qi Xu, Herren Wu, Changshou Gao, Nazzareno Dimasi, Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides Journal of Controlled Release. ,vol. 220, pp. 660- 670 ,(2015) , 10.1016/J.JCONREL.2015.09.032